HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026
Company leaders to share perspectives on multispecific Fc-fusion therapeutics, AI-enabled development, and CMC strategy for emerging biologic modalities
HanchorBio will participate in Biologics World Taiwan 2026, to be held on March 25-26 at Hilton Taipei Sinban, Taiwan. At the event, Dr. Scott Liu, Founder, Chairman, and CEO, and Dr. Vivian Kuo, Executive Director, CMC, will join the speaker faculty to share perspectives on next-generation biologics innovation, spanning multispecific Fc-fusion therapeutics, translational development, and CMC strategy for emerging drug modalities.
Event Information
- Date: March 25–26, 2026
- Location: Hilton Taipei Sinban, Taiwan
HanchorBio’s participation reflects the company’s continued focus on advancing differentiated biologics designed to address complex disease biology through precision protein engineering, translational development, and disciplined execution across CMC and manufacturing. This effort is further supported by the company’s growing AI and Decision Science capabilities, which are being applied across structural biology, development strategy, and CMC decision-making.
Speaker Session(s)
March 25, 2026 | 11:25
Dr. Liu will present “Innovation in Immuno-Oncology through Development of Tri-specific Fc Fusion Proteins: From Discovery to IND Filing.”
His presentation will discuss the therapeutic rationale for multispecific Fc-fusion design, development considerations from discovery through IND-enabling stages, and the broader potential of these formats in next-generation immuno-oncology.
March 25, 2026 | 13:55
Dr. Kuo will present “From Complexity to Control: Process and CMC Excellence for the Next-Generation Innovative Drugs.”
Her session will focus on process and CMC challenges related to emerging biologic modalities, approaches for improving development control and manufacturability, and selected applications of AI-enabled modeling and decision support in development strategy. It will also highlight HanchorBio’s broader effort to incorporate AI and Decision Science into biologics development, including applications in structural biology and CMC optimization.
HanchorBio looks forward to engaging with industry peers, potential partners, and investors at the meeting, and to contributing to the broader discussion on how platform innovation can be translated into clinically meaningful therapeutic progress.
About Biologics World Taiwan 2026
Biologics World Taiwan is a prominent industry forum that brings together stakeholders involved in biologics research, development, manufacturing, and clinical translation. Held at a time when Taiwan is further advancing its biomedicine and biomanufacturing capabilities, the event offers a valuable platform for industry leaders, innovators, and investors to share perspectives on the future of biologics both across Asia and the global market.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/PD-L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.